These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18158710)

  • 1. Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
    Steiner G
    Diab Vasc Dis Res; 2007 Dec; 4(4):368-74. PubMed ID: 18158710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is it time to stop treating dyslipidaemia with fibrates?
    Benatar JR; Stewart RA
    N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M
    Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I; Krone W
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS
    Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.
    Wanner C; Krane V
    Kidney Blood Press Res; 2011; 34(4):209-17. PubMed ID: 21691123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role for fibrate therapy in diabetes: evidence before FIELD.
    Vergès B
    Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrates after the FIELD study: Some answers, more questions.
    Wierzbicki AS
    Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [On behalf and the extent of evidence].
    Ruiz J
    Rev Med Suisse; 2010 Jun; 6(252):1171-2. PubMed ID: 20614750
    [No Abstract]   [Full Text] [Related]  

  • 11. Diabetic dyslipidemia: a practical guide to therapy.
    Tovar JM; Bazaldua OV; Loffredo A
    J Fam Pract; 2008 Jun; 57(6):377-88. PubMed ID: 18544321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis.
    Candido R; Zanetti M
    Ital Heart J; 2005 Sep; 6(9):703-20. PubMed ID: 16212072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interactions between statins and fibrates.
    Corsini A; Bellosta S; Davidson MH
    Am J Cardiol; 2005 Nov; 96(9A):44K-49K; discussion 34K-35K. PubMed ID: 16291014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of lipid-lowering drug therapy in children and adolescents.
    Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.
    Judge EP; Phelan D; O'Shea D
    J R Soc Med; 2010 Sep; 103(9):357-62. PubMed ID: 20807991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrates: where are we now?
    Seth Loomba R; Arora R
    Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.